ISPO

Published in Cancer Detection and Prevention 1996; 20(2):94-102.

Preliminary Report: The Short-Term Effects of Direct p53 DNA Injection in Primary Hepatocellular Carcinomas

N. A. Habib, Ch.M., F.R.C.S. a,b, S.-F. Ding, M.D., Ph.D. a, R. El-Masry, M.D., F.R.C.S. b, R. R. Mitry, B.S. a, K. Honda, M.D. a, N. E. Michail, M.D.c, G. Dalla Serra, M.D. a, G. Izzi, M.D. a, L. Greco, M.D. a, M. Bassyouni, M.D. b, M. El-Toukhy, M.D. b, and Y. Abdel-Gaffar, M.D. d

a Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom; b Department of Surgery and Radiology, Al- Hayat Medical Centre, Cairo, Egypt; c Theodor Bilharz Institute, Cairo, Egypt; and d Department of Hepatology, Liver Institute, Egypt

Address all correspondence and reprint requests to: Nagy A. Habib, Ch.M., F.R.C.S., Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 ONN, United Kingdom.

ABSTRACT: A pilot study, to assess the therapeutic potential of percutaneous injection of wild-type p53 (wt-p53) in five patients with primary hepatocellular carcinoma is reported. Three of the five patients showed objective tumor response with reduction of the tumor volume on computed tomographic (CT) scan measurements as well as a significant fall of serum alphafetoprotein. Much further work will be needed to elucidate the mechanism of action.

KEY WORDS: tumor suppressor genes, p53, direct DNA injection, gene therapy, hepatocellular carcinoma, liver tumor.

http://www.cancerprev.org/Journal/Issues/20/2/118